This page shows the latest Valneva news and features for those working in and with pharma, biotech and healthcare.
Valneva has its own chikungunya vaccine candidate in late-stage development, VLA1553. ... A Biologic License Application for Valneva’s candidate is currently under priority review by the US Food and Drug Administration, with a Prescription Drug User
Valneva has reported additional data from a small exploratory study of its COVID-19 booster vaccine, VLA2001, for people aged 18 years and older. ... Juan Carlos Jaramillo, Valneva’s chief medical officer, said: “While these latest booster results
Valneva’s chikungunya vaccine candidate, VLA1553, has shown promising 12-month antibody persistence results after a single-dose, the vaccine company reported. ... A dedicated antibody persistence trial, VLA1553-303, was set up by Valneva to confirm the
Pfizer and Valneva have reported antibody persistence data six months after the completion of a three or two-dose vaccination schedule with their Lyme disease vaccine candidate, VLA15, in both children ... In August, Pfizer and Valneva announced they had
Valneva further expects to report additional clinical data in the fourth quarter of 2022, notably heterologous booster data, which may potentially support the positioning of its inventory. ... Valneva currently has agreements to supply VLA2001 to certain
People aged 18 to 29 years old who received Valneva produced even more neutralising antibodies, following two doses of the vaccine. ... Initial results are available and indicate that the Valneva vaccine produces fewer neutralising antibodies against the
More from news
Approximately 21 fully matching, plus 11 partially matching documents found.
The Vivalis shareholders will own 55 per cent of the new company called Valneva based in Lyon and the Intercell shareholders will obtain a 32 per cent premium for their shares.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Appoints David Lawrence and Wolfgang Bender. Commercial stage biotech Valneva has appointed David Lawrence and Wolfgang Bender, a move that will strengthen the senior management team for future growth.
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
No results were found
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...